Cogent Biosciences (COGT) Enterprise Value (2017 - 2021)
Cogent Biosciences has reported Enterprise Value over the past 5 years, most recently at -$202.9 million for Q3 2021.
- Quarterly results put Enterprise Value at -$202.9 million for Q3 2021, down 56.77% from a year ago — trailing twelve months through Sep 2021 was -$202.9 million (down 56.77% YoY), and the annual figure for FY2020 was -$242.2 million, down 547.15%.
- Enterprise Value for Q3 2021 was -$202.9 million at Cogent Biosciences, up from -$218.1 million in the prior quarter.
- Over the last five years, Enterprise Value for COGT hit a ceiling of -$487000.0 in Q1 2020 and a floor of -$242.2 million in Q4 2020.
- Median Enterprise Value over the past 5 years was -$80.8 million (2018), compared with a mean of -$98.0 million.
- Biggest five-year swings in Enterprise Value: surged 99.27% in 2020 and later crashed 47279.67% in 2021.
- Cogent Biosciences' Enterprise Value stood at -$28.3 million in 2017, then plummeted by 245.55% to -$97.9 million in 2018, then surged by 61.79% to -$37.4 million in 2019, then tumbled by 547.15% to -$242.2 million in 2020, then grew by 16.23% to -$202.9 million in 2021.
- The last three reported values for Enterprise Value were -$202.9 million (Q3 2021), -$218.1 million (Q2 2021), and -$230.7 million (Q1 2021) per Business Quant data.